Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

9176b038-65e3-469d-a867-d99bc732e45d

79472fa7-9f41-5efd-938a-07fde3580c41

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
age_years
80

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • WNT_BETA_CATENIN_SIGNALING+0.310
  • HEDGEHOG_SIGNALING+0.220
  • NOTCH_SIGNALING+0.220
  • P53_PATHWAY+0.190
  • IL6_JAK_STAT3_SIGNALING+0.180
  • ESTROGEN_RESPONSE_EARLY+0.160
  • MYOGENESIS+0.160
  • COAGULATION+0.150
  • KRAS_SIGNALING_DN+0.150
  • XENOBIOTIC_METABOLISM+0.080

Top 10 suppressed

  • E2F_TARGETS-0.500
  • G2M_CHECKPOINT-0.500
  • MYC_TARGETS_V1-0.500
  • MTORC1_SIGNALING-0.470
  • ANDROGEN_RESPONSE-0.410
  • PROTEIN_SECRETION-0.400
  • OXIDATIVE_PHOSPHORYLATION-0.380
  • CHOLESTEROL_HOMEOSTASIS-0.340
  • INTERFERON_ALPHA_RESPONSE-0.320
  • MYC_TARGETS_V2-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-1121
medullo-epn-umap@date-based
MedMedulloblastoma0.908
2TCGA-A7-A426-01A-22R-A24H-07
breast-umap@18
A0.890
3TCGA-D8-A3Z5-01A-41R-A24H-07
breast-umap@18
A0.883
4MDT-AP-1356
medullo-epn-umap@date-based
MedMedulloblastoma0.875
5MNG1258
mng-umap@100
0.866
6d406bb03-1a9a-4aa3-a1a8-4de5478b4701
colon-landscapes@1
0.865
7MBCProject_0003_T2_RNA
breast-umap@18
A0.863
8MDT-AP-1132
medullo-epn-umap@date-based
MedMedulloblastoma0.860
9TCGA-A2-A0CK-01A-11R-A22K-07
breast-umap@18
A0.852
10TCGA-AC-A3W7-01A-11R-A22K-07
breast-umap@18
A0.850

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 14 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
WNT_BETA_CATENIN_SIGNALING0.310Inavolisib— uncovered
HEDGEHOG_SIGNALING0.220Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
P53_PATHWAY0.190Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.160Inavolisib— uncovered
MYOGENESIS0.160Inavolisib— uncovered
COAGULATION0.150Binimetinib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.080Inavolisib— uncovered
APICAL_JUNCTION0.050Inavolisib— uncovered
APICAL_SURFACE0.030Temsirolimus— uncovered
KRAS_SIGNALING_UP0.020Inavolisib— uncovered
PANCREAS_BETA_CELLS0.010Cobimetinib— uncovered